TRPA1 and rheumatoid arthritis: The synthetic cannabinoid agonist, WIN55,212-2 mesylate, reduces the release of inflammatory mediators, such as interleukin (IL)-6, IL-8, and matrix metalloproteinase (MMP)-3, in RA synovial fibroblasts via a TRPA1-dependent mechanism [91].